Publications 2012-2015

BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.

Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H, Gardin C.  Oncotarget . 2015;6(19):17698-712.

Fsn0503h antibody-mediated blockade of cathepsin S as a therapeutic strategy for the treatment of solid tumors.

Vazquez R, Astorgues-Xerri L, Bekradda M, Gormley J, B uick  R, Kerr P, Cvitkovic E, Raymond E, D’Incalci M, Frapolli R and Riveiro ME.  Biochimie.   2015;18,101-7.

The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted Drugs.

Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, Rinaldi A, Testoni M, Cascione L, Ponzoni M, Mensah AA, Stathis A, Stussi G, Riveiro ME, Herait P, Inghirami G, Cvitkovic E, Zucca E, Bertoni F. Clin Cancer Res. 2015;21(7):1628-38. 

OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumor angiogenesis.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, Vidaud M, de Gramont A, Martinet M, Cvitkovic E, Faivre S, Raymond E.  Eur J Cancer . 2014;50(14):2463-77.

Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples.

Odore E, Lokiec F, Weill S, Noel J, Herait P, Bekradda M, Riveiro ME and Rezai K.  Anal Methods.  2014;6:9108-15.

Unraveling galectin-1 as a novel therapeutic target for cancer.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S.  Cancer Treat Rev . 2014;40(2):307-19. Review.

New insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.

Ghanem I, Riveiro ME, Paradis V, Faivre S, Vázquez de Parga PM and Raymond E.  Am J Transl Res . 2014;6(4):340-52.

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.

Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.  Cancer Chemother Pharmacol . 2013;71(5):1297-307.

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E.  Mar Drugs . 2013;11(3):944-59.

Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models in Galectins and Disease Implications for Targeted Therapeutics.

Raymond E, Astrorgue-Xerri L, Serova M, Riveiro ME, Faivre S. Chapter 15, pp 259–266 ACS Symposium Series, Vol. 1115. ISBN13: 9780841228801. eISBN: 9780841228818. December 18, 2012 Book Chapter.  

Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.

Albert S, Riveiro ME, Halimi C, Hourseau M, Couvelard A, Serova M, Barry B, Raymond E, Faivre S.  Head Neck . 2013;35(12):1819-28.

Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.

Albert S, Hourseau M, Halimi C, Serova M, Descatoire V, Barry B, Couvelard A, Riveiro ME, Tijeras-Raballand A, de Gramont A, Raymond E, Faivre S.  Oral Oncol . 2012;48 (12):1263-71.